



An efficient synthesis of (+)-oxybiotin from D-arabinose


Velimir Popsavin,* Goran Benedeković and Mirjana Popsavin

University of Novi Sad, Faculty of Sciences, Institute of Chemistry, Trg D. Obradovića 3, YU-21000 Novi Sad, Yugoslavia

Received 22 December 2001; revised 21 January 2002; accepted 30 January 2002

Abstract—A novel stereospecific synthesis of (+)-oxybiotin a biologically active analogue of (+)-biotin has been achieved starting from D-arabinose through ten synthetic steps. © 2002 Elsevier Science Ltd. All rights reserved.

The oxygenated analogue of biotin in which oxygen replaces sulphur was synthesised by Hofmann¹ and named oxybiotin.² Like biotin itself, oxybiotin supports the growth of some microorganisms whereupon it has been confirmed that the analogue is not converted to biotin *in vivo*.³ On the basis of such a similar biological activity it was assumed that oxybiotin has the same absolute configuration as that of biotin.¹ This assumption was definitely confirmed by a total synthesis of optically active (+)-oxybiotin (**1**, Scheme 1), which was achieved starting from D-glucose in 19 synthetic steps.⁴ An alternative synthesis of (+)-**1** was recently accomplished in our laboratory starting from D-xylose.^{5,6} This approach consists of 14 synthetic steps, but contains a low-yielding step in the final stage of the synthesis.⁶ We now report on an efficient ten-step synthesis of (+)-oxybiotin (**1**) based on D-arabinose as a chiral precursor.




Scheme 1. Functional and stereochemical relationship of (+)-oxybiotin (**1**) and D-arabinose.

Keywords: D-arabinose; 2,5-anhydro-D-ribose; (+)-oxybiotin; stereospecific synthesis; Wittig reaction; ring contraction.

* Corresponding author. Fax: +381-21-54-065; e-mail: popsavin@ih.ns.ac.yu, popsavin@hotmail.com

A visual examination of the target molecule **1** reveals a chiral tetrahydrofuran system containing three contiguous substituents including the carboxybutyl side chain at C-2, as well as the C-3 and C-4 nitrogen functions incorporated into a *cis*-fused imidazolidinone ring. At first glance this leads to a pentose-type precursor in which the desired carboxyalkyl side chain should be elaborated at C-1, while the tetrahydrofuran ring should be closed between the O-5 and C-2. In view of the configuration at C-2 in (+)-**1** and the O-5/C-2 cyclisation step that should occur, the absolute configuration at this particular stereocentre in the starting monosaccharide is crucial. It corresponds to the (*S*)-configuration at C-2 in D-arabinose, if the inversion of configuration occurs at this centre during the ring closure step. The absolute configuration at C-3 and C-4 in D-arabinose is also suitable for successive introduction of two nitrogen functions, with inversion of configuration at these positions that would enable completion of the synthesis. Hence, a novel stereospecific synthesis of (+)-oxybiotin from D-arabinose was planned based on the trisubstituted tetrahydrofuran **7** as a possible intermediate. It was further assumed that the key intermediate **7** could be obtained from the 2,5-anhydro-D-ribose derivative **4**, by a sequential C-1 deprotection/Wittig elongation manoeuvre. Compound **4** should be available by a ring contraction in the arabinopyranoside 2-triflate **3**, analogously to similar literature precedents.⁷ An alternative approach to **7** assumes an intramolecular displacement of the allylic C-2 mesyloxy group in the acyclic ester **10a** (Scheme 3), which should be available from the protected D-arabinose derivative **10** via a Wittig reaction.


The five-step route to the key intermediate **7** via the 2,5-anhydro-D-ribose derivative **4** is outlined in Scheme 2.



Scheme 2. (a) Tf_2O , Py, CH_2Cl_2 , -10°C , 0.5 h; (b) KOBz, DMF, rt, 24 h, 99% from **2**; (c) MeONa, MeOH, rt, 1.5 h; (d) $\text{Ph}_3\text{P}:\text{CHCH}:\text{CHCO}_2\text{Me}$, MeOH, rt, 1.5 h, 41% from **4**; (e) H_2 , PtO_2 , MeOH, rt, 24 h, 88%.

In 1989 Baer, Mateo and Siemsen⁷ reported a facile formation of 2,5-anhydro-6-deoxy-L-talose derivatives by ring contraction in methyl 2-*O*-trifluoromethanesulfonyl- β -L-fucopyranoside under solvolytic conditions. It was therefore assumed that utilisation of similar methodology in the D-arabinopyranose series would lead to the formation of the desired intermediate **4**. Accordingly, the preparation of the 2-triflic ester **3** was attempted. The known⁸ methyl 3,4-*O*-isopropylidene- β -D-arabinopyranoside (**2**) was treated with triflic anhydride to afford the expected 2-*O*-triflic ester **3**. Compound **3** was characterised from NMR spectroscopic data, but was rather unstable on storage, similar to its fucopyranoside analogues.⁷ It was therefore, immediately after its rapid isolation, treated with potassium benzoate in *N,N*-dimethylformamide for 24 h at room temperature. The desired product **4** was obtained as an inseparable 2:1 mixture of C-1 epimers in an almost quantitative yield. Treatment of **4** with sodium methoxide, followed by a Wittig reaction with 3-(methoxycarbonyl)-2-propenylidene triphenylphosphorane⁹ in methanol, gave the unsaturated ester **6** as an inseparable mixture of several *E*- and *Z*-isomers. Catalytic hydrogenation of **6** over PtO_2 in methanol furnished the corresponding saturated ester **7** in 36% overall yield with respect to the starting compound **2**.

In a different approach towards the intermediate **7**, 3,4-*O*-isopropylidene-D-arabinose (**8**), readily available from D-arabinose,¹⁰ was used as the starting material (Scheme 3). Treatment of **8** with mesyl chloride and triethylamine in dry dichloromethane gave the crystalline glycosyl chloride **9** as the only reaction product. Although compound **9** could be stored at -20°C for weeks without change, it tended to decompose on standing at room temperature turning into a tar. Hence, the intermediate **9** was immediately treated with silver oxide in aqueous acetone, in the presence of a catalytic amount of silver triflate, to give the stable lactol **10** (94% from **8**). Treatment of **10** with 3-(carboxymethoxy)-2-propenylidene triphenylphosphorane in *N,N*-dimethylformamide, in the presence of calcium carbonate as a proton acceptor, gave an inseparable mixture of unsaturated esters **6** (*E*- and *Z*-isomers), as a result of the sequential Wittig reaction/intramolecular displacement process.¹¹ Neither the acyclic intermediate **10a** nor the products of the competitive Michael addition could be detected in the reaction mixture. The ^1H and ^{13}C NMR spectra of the mixture of **6** obtained displayed essentially the same signals as the sample **6** prepared according to Scheme 2, but indicated a somewhat different ratio of *E*- and *Z*-isomers. Moreover, catalytic hydrogenation of **6**, under the same reaction



Scheme 3. (a) MsCl , Et_3N , CH_2Cl_2 , -10°C , 0.5 h; (b) Ag_2O , AgOTf , aq. Me_2CO , rt, 24 h, 94% from **8**; (c) $\text{Ph}_3\text{P}:\text{CHCH}:\text{CHCO}_2\text{Me}$, CaCO_3 , DMF, 135°C , 2 h; (d) H_2 , PtO_2 , MeOH, rt, 24 h, 67% from **10**.

conditions as described above, gave a good yield of the corresponding saturated ester **7** (67% from **10**).

The four-step sequence outlined in Scheme 3 represents a more convenient route towards the key intermediate **7**, since it provided a considerably higher overall yield (63% from **8**) compared to the alternative five-step sequence presented in Scheme 2 (36% from **2**). Final conversion of the intermediate **7** into (+)-oxybiotin (**1**) is shown in Scheme 4.

Hydrolytic removal of the isopropylidene protective group in **7** gave an excellent yield of the expected diol **11** (95%). The optical rotation, as well as the IR and NMR spectral data of product **11** thus obtained were in good agreement with those already reported.^{5,6} Compound **11** was further converted to the corresponding 3,4-diazido derivative **13** under reaction conditions similar to those reported earlier.⁵ Reaction of **11** with triflic anhydride in pyridine and dichloromethane gave the corresponding 3,4-ditriflate **12**, isolated by flash column chromatography in 50% yield. Subsequent treatment of **12** with sodium azide in HMPA afforded the corresponding 3,4-diazido derivative **13** as the only reaction product (47% from **11**). However, when the last two-step sequence was carried out without purification of the intermediate **12**, the desired product **13** was obtained in a considerably higher overall yield (68% from **11**).¹²

Compound **13** represents a convenient intermediate for the completion of the synthesis of target **1**, since it has the correct absolute configuration at all the stereocentres, as well as the *cis* azido functions suitable for the final imidazolidinone ring closure. This requires conversion of **13** into the corresponding diamine, followed by subsequent cyclisation of the intermediate upon treatment with phosgene or its equivalent. Diazide **13** was


therefore reduced over PtO₂ in dichloromethane and after 22 h, when the TLC indicated complete conversion of **13**, the reaction mixture was treated with triphosgene, under reaction conditions similar to those recently applied for the conversion of vicinal amino alcohols to oxazolidinones,¹³ whereby the imidazolidinone **14** was obtained in 66% yield. Treatment of **14** with an aqueous solution of sodium hydroxide, followed by neutralisation with Amberlyst 15, gave an almost quantitative yield of (+)-oxybiotin (**1**), with physical constants¹⁴ in excellent agreement with those already reported.⁴ Spectroscopic data¹⁵ of the final product thus obtained were consistent with structure **1**.

The overall yield of (+)-oxybiotin (**1**) from D-arabinose by the combined routes presented in Schemes 3 and 4 was 22%.

In conclusion, this paper reports a convenient ten-step synthesis of (+)-oxybiotin by chirality transfer from D-arabinose. The synthesis was realised by using simple and conventional experimental procedures, as well as a cheap and readily available starting material.¹⁶ In addition, the new approach provided a convenient one-pot procedure for the construction of the (+)-oxybiotin ureido system by using triphosgene, a safe and stable replacement of phosgene.¹⁷

Acknowledgements

This work was supported by a research grant from the Ministry of Science, Technologies and Development of the Republic of Serbia. The authors are grateful to Mrs. T. Marinko-Covell (University of Leeds, UK) for recording the mass spectra.



Scheme 4. (a) 9:1 TFA–H₂O, rt, 0.5 h, 95%; (b) Tf₂O, Py, CH₂Cl₂, 0°C, 1.5 h; (c) NaN₃, HMPA, rt, 1.5 h, 68% from **11**; (d) H₂, PtO₂, CH₂Cl₂, rt, 24 h, then (Cl₃CO)₂CO, Et₃N, 0°C, 2 h, rt 22 h, 66%; (e) NaOH, H₂O, 100°C, 1 h, then Amberlyst 15, rt, 0.5 h, 99%.

References

- Hofmann, K. *J. Am. Chem. Soc.* **1945**, *67*, 1459–1462.
- In a review related to the chemistry of biotin-dependent enzymes the oxygenated analogue was named *O*-heterobiotin; see: Knowles, J. R. *Annu. Rev. Biochem.* **1989**, *58*, 195–221. However, the original name seems to be still in use according to some more recent references; see for example: DeTitta, G. T.; Blessing, R. H.; Moss, G. R.; King, H. F.; Sukumaran, D. K.; Roskwitalski, R. L. *J. Am. Chem. Soc.* **1994**, *116*, 6485–6493.
- Dyke, S. F. In *Chemistry of Natural Products*; Bentley, K. W., Ed.; Interscience: London, 1964; Vol. 6, pp. 161–181.
- Ohrui, H.; Kuzuhara, H.; Emoto, S. *Agric. Biol. Chem.* **1971**, *35*, 752–755.
- Miljković, D.; Popsavin, V.; Harangi, J. *Tetrahedron Lett.* **1987**, *28*, 5733–5736.
- Popsavin, V.; Benedeković, G.; Popsavin, M.; Miljković, D. *Carbohydr. Res.* **2002**, *337*, 459–465.
- Baer, H. H.; Mateo, F. H.; Siemsen, L. *Carbohydr. Res.* **1989**, *187*, 67–92.
- Jones, J. K. N.; Nicholson, W. H. *J. Chem. Soc.* **1955**, 3050–3055.
- Buchta, E.; Andree, F. *Chem. Ber.* **1959**, *92*, 3111–3115.
- Kiso, M.; Hasegawa, A. *Carbohydr. Res.* **1976**, *52*, 95–102.
- Conversely, the reaction of **10** with trimethyl-4-phosphono crotonate, in the presence of NaH in THF, at room temperature for 0.5 h, gave pure *E,E*-**6** (48%) as the only stereoisomer: mp 75°C (from CH₂Cl₂–hexane), $[\alpha]_D$ –108.2 (*c* 0.88 in CHCl₃); ν_{\max} (KBr): 1710, 1650, 1630 cm⁻¹; ¹H NMR (CDCl₃): δ 1.32 and 1.51 (2×s, 3H each, Me₂C), 3.73 (s, 3H, CO₂Me), 3.83 (dd, 1H, *J*_{5a,5b} 10.7, *J*_{4,5a} 4.2 Hz, H-5a), 3.99 (dd, 1H, *J*_{4,5b} 1 Hz, H-5b), 4.58 (dd, 1H, *J*_{2,3} 1.7, *J*_{3,4} 6.2 Hz, H-3), 4.62 (ddd, 1H, *J*_{2,2'} 1.8, *J*_{1',2} 4.6 Hz, H-2), 4.77 (m, 1H, H-4), 5.88 (d, 1H, *J*_{3',4'} 15.4 Hz, H-4'), 5.97 (dd, 1H, *J*_{1',2'} 15.5 Hz, H-1'), 6.39 (ddd, 1H, *J*_{2',3'} 11 Hz, H-2'), 7.24 (dd, 1H, H-3'); ¹³C NMR (CDCl₃): δ 24.91 and 26.48 (Me₂C), 51.53 (CO₂Me), 72.53 (C-5), 80.84 (C-4), 83.92 (C-2), 84.76 (C-3), 112.90 (Me₂C), 121.75 (C-4'), 128.83 (C-2'). 138.02 (C-1'), 143.23 (C-3'), 167.09 (CO₂Me). FAB MS: *m/z* 277 (M⁺+Na); HR MS (ES⁺): *m/z* 277.1052 (M⁺+Na). Calcd for C₁₃H₁₈O₅Na: 277.1052.
- Compound **13** (oil): $[\alpha]_D$ +36.0 (*c* 1.95 in CHCl₃); ν_{\max} (film): 2100, 1740 cm⁻¹; ¹H NMR (CDCl₃): δ 1.29–1.78 (m, 6H, 3×CH₂), 2.33 (t, 2H, CH₂CO₂Me), 3.66 (s, 3H, CO₂Me), 3.78 (dd, 1H, *J*_{5a,5b} 9.1, *J*_{4,5a} 7.2 Hz, H-5a), 3.88 (ddd, 1H, *J*_{1'a,2} 5.8, *J*_{1'b,2} 7.3, *J*_{2,3} 3.4 Hz, H-2), 3.95–4.05 (two partially overlapped dd, 2H, *J*_{3,4} 7.7, *J*_{4,5b} 4 Hz, H-3 and H-5b), 4.25 (td, 1H, H-4); ¹³C NMR (CDCl₃): δ 24.76, 25.47 and 29.68 (3×CH₂), 33.72 (CH₂CO₂Me), 51.46 (CO₂Me), 62.96 (C-4), 65.24 (C-3), 68.52 (C-5), 80.78 (C-2), 173.87 (CO₂Me). FAB MS: *m/z* 291 (M⁺+Na); HR MS (ES⁺): *m/z* 291.1174 (M⁺+Na). Calcd for C₁₀H₁₆N₆O₃Na: 291.1182.
- (a) Mitchell, S. A.; Oates, B. D.; Razavi, H.; Polt, R. *J. Org. Chem.* **1998**, *63*, 8837–8842; (b) Falb, E.; Bechor, Y.; Nudelman, A.; Hassner, A.; Albreck, A.; Gottlieb, H. E. *J. Org. Chem.* **1999**, *64*, 498–506.
- Physical constants of (+)-**1**: mp 187–188°C (from H₂O), $[\alpha]_D$ +57.8 (*c* 0.65 in 1 M NaOH); Ref. 4: mp 187–188°C, $[\alpha]_D$ +57.7.
- Spectroscopic data of (+)-**1**: ν_{\max} (KBr): 3430–2500, 1700, 1670, 1490, 1460, 1250, 1200, 1070 and 1020 cm⁻¹; ¹H NMR (D₂O): δ 1.41–1.80 (m, 6H, 3×CH₂), 2.46 (t, 2H, *J* 7 Hz, CH₂CO₂H), 3.64–3.76 (partially overlapped dd and m, 2H, *J*_{2,3} 4, *J*_{5a,5b} 10.4, *J*_{4,5a} 4.4 Hz, H-2 and H-5a), 3.94 (d, 1H, H-5b), 4.42 (dd, 1H, *J*_{3,4} 8.7 Hz, H-3), 4.45 (dd, 1H, H-4); ¹³C NMR (D₂O): δ 26.96, 27.66 and 30.42 (3×CH₂), 36.36 (CH₂CO₂H), 60.35 and 61.67 (C-3 and C-4), 76.55 (C-5), 85.64 (C-2), 167.63 (NHCONH), 181.73 (CO₂H). FAB MS: *m/z* 251 (M⁺+Na); HR MS (ES⁺): *m/z* 251.1007 (M⁺+Na). Calcd for C₁₀H₁₆N₂O₄Na: 251.1008.
- Bols, M. *Carbohydrate Building Blocks*; Wiley: New York, 1996; pp. 10–15.
- Eckert, H.; Foster, B. *Angew. Chem., Int. Ed. Engl.* **1987**, *26*, 894–895.